


10/585772  
AP20 Rec'd PCT/PTO 12 JUL 2006

PATENT  
ATTORNEY DOCKET NO. 50120/008001

Certificate of Mailing	
Date of Deposit: <u>July 12, 2006</u>	Label Number: <u>EV768765377US</u>
I hereby certify under 37 C.F.R. § 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
<u>Elvis De La Cruz</u> Printed name of person mailing correspondence	 Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Young et al.	Confirmation No.:	Not yet assigned
Serial No.:	Not yet assigned	Art Unit:	Not yet assigned
Filed:	July 12, 2006	Examiner:	Not yet assigned
Customer No.:	21559		
Title:	ANTISENSE OLIGONUCLEOTIDES DIRECTED TO RIBONUCLEOTIDE REDUCTASE R2 AND USES THEREOF IN COMBINATION THERAPIES FOR THE TREATMENT OF CANCER		

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed, with the exception of U.S. patents and U.S. patent application publications. A copy of a search report and written opinion from a corresponding international application is also enclosed.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

10/385772


This statement is being filed with the application. RECEIVED JUL 13 JUL 2006

If there are any charges or any credits, please apply them to Deposit Account

No. 03-2095.

Respectfully submitted,

Date: 12 July 2006

  
\_\_\_\_\_  
Kristina Bieker-Brady, Ph.D.  
Reg. No. 39,109

KAREN L. ELBING  
FOR  
LEB NO. 238

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045

USPTO Rec'd PGT/PTO 12 JUL 2006

Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 (MODIFIED)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	Attorney Docket No.	101/585772
	Serial No.	Not Yet Assigned
	Applicant	Young et al.
	Filing Date	July 12, 2006
	Group	Not Yet Assigned
	IDS Filed	July 12, 2006
Customer No.	21559	

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	WO 98/00532	Jan. 8, 1998	WIPO			
	WO 00/47733	Aug. 17, 2000	WIPO			
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
	Agrawal et al., "Antisense and/or Immunostimulatory Oligonucleotide Therapeutics," <i>Current Cancer Drug Targets</i> 1:197-209 (2001).					
	Lee et al., "GTI-2040, an Antisense Agent Targeting the Small Subunit Component (R2) of Human Ribonucleotide Reductase, Shows Potent Antitumor Activity Against a Variety of Tumors," <i>Cancer Research</i> 63:2802-2811 (2003).					
	Lepoivre et al., "Alterations of Ribonucleotide Reductase Activity Following Induction of the Nitrite-Generating Pathway in Adenocarcinoma Cells," <i>The Journal of Biological Chemistry</i> 265:14143-14149 (1990).					
	Mader et al., "Transcription and Activity of 5-Fluorouracil Converting Enzymes in Fluoropyrimidine Resistance in Colon Cancer <i>In Vitro</i> ," <i>Biochem. Pharm.</i> 54:1233-1242 (1997).					
	Pavloff et al., "Sequence Analysis of the Large and Small Subunits of Human Ribonucleotide Reductase," <i>J. DNA Sequencing and Mapping</i> , 2:227-234 (1992).					
	Vose et al., "Update on Epidemiology and Therapeutics for Non-Hodgkin's Lymphoma," <i>Hematology Am. Soc. Hematol. Educ. Program</i> 241-262 (2002).					

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	